ASLAN Pharmaceuticals (ASLN) Announces Filing for Proposed ADS IPO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Aslan Pharmaceuticals Files for Proposed Initial Public Offering in the U.S.
March 26, 2018 9:00 PM EDTSINGAPORE, March 26, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its American Depository Shares (ADSs) in the United States.
ASLAN has applied to list its ADSs on The Nasdaq Global Market under the trading... More



